Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder
- PDF / 1,255,056 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 28 Downloads / 181 Views
ORIGINAL ARTICLE
Survival of contemporary patients with non‑metastatic urachal vs. non‑urachal adenocarcinoma of the urinary bladder Stefano Luzzago1,2 · Carlotta Palumbo1,3 · Giuseppe Rosiello1,4 · Angela Pecoraro1,5 · Marina Deuker1,6 · Francesco Alessandro Mistretta1,2 · Zhe Tian1 · Gennaro Musi2 · Emanuele Montanari7 · Shahrokh F. Shariat8,9,10,11,12 · Fred Saad1 · Alberto Briganti4 · Ottavio de Cobelli2,13 · Pierre I. Karakiewicz1 Received: 3 September 2019 / Accepted: 6 January 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose To test the effect of tumor location (urachal vs. non-urachal) on cancer-specific mortality (CSM) in patients with adenocarcinoma of the urinary bladder (ADKUB). Materials and methods Within the Surveillance, Epidemiology, and End Results registry (2004–2016), we identified patients with non-metastatic (≤ T4N0M0) ADKUB. Stratification was made according to tumor location: urachal vs. non-urachal ADKUB. Kaplan–Meier plots and multivariable Cox regression models were fitted before and after 1:3 propensity score (PS) matching and separate Cox regression models were refitted before and after inverse probability of treatment weighting (IPTW). Results Of 1681 patients, 226 (13.5%) vs. 1455 (86.5%) harboured urachal vs. non-urachal ADKUB, respectively. Fiveyear cancer-specific survival (CSS) rates were, respectively, 75 vs. 67% for urachal vs. non-urachal ADKUB (p = 0.001). In subgroup analyses of ≤ T2N0M0 patients, 5-year CSS rates were, respectively, 84 vs. 73% for urachal vs. non-urachal ADKUB (p = 0.006). In subgroup analyses of T3-4N0M0 patients, 5-year CSS rates were, respectively, 68 vs. 49% for urachal vs. non-urachal ADKUB (p
Data Loading...
